Akèy › Kansè pwostat › Wisconsin › Madison
Etid klinik pou Kansè pwostat nan Madison, WI
29 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Madison (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- University of Wisconsin Carbone Cancer Center, Madison
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Ap rekriteFaz 3
- William S Middleton VA Medical Center, Madison
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
PET/CT Characterization of Treatment Resistance
Ap rekrite
- University of Wisconsin, Madison
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Ap rekriteFaz 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Ap rekriteFaz 2
- William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Ap rekriteFaz 2
- William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Ap rekriteFaz 3
- University Hospital and UW Health Clinics ( Site 0065), Madison
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Ap rekriteFaz 2
- Carbone Cancer Center University of Wisconsin-Madison, Madison
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Ap rekriteFaz 3
- University of Wisconsin, Madison
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Ap rekriteFaz 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Ap rekriteFaz 2
- UW Health Carbone Cancer Center, Madison
COMPASS Study for Metastatic Castration-resistant Prostate Cancer
Ap rekriteEtid obsèvasyon
- University of Wisconsin Carbone Cancer Center, Madison
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
Ap rekriteFaz 2
- University of Wisconsin Carbone Cancer Center-Madison, Madison
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Ap rekriteFaz 3
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- University of Wisconsin, Carbone Cancer Center, Madison
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Ap rekriteFaz 1
- University of Wisconsin Carbone Cancer Center, Madison
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
Ap rekriteEtid obsèvasyon
- University of Wisconsin-Madison, Madison
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Ap rekriteFaz 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
Ap rekriteFaz 2
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Ap rekriteFaz 1
- University of Wisconsin, Madison
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Ap rekriteFaz 1
- University of Wisconsin Carbone Cancer Center, Madison
Using FAPI PET/MRI to Evaluate Prostate Cancer
Ap rekriteFaz 2
- University of Wisconsin, Madison
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Ap rekriteEtid obsèvasyon
- University of Wisconsin Carbone Cancer Center, Madison
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Ap rekriteFaz 2/3
- William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison
Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer
Ap rekriteFaz 1
- University of Wisconsin Carbone Cancer Center (UWCCC) - Cancer Connect, Madison
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
Ap rekriteFaz 1
- University of Wisconsin - Madison, Madison
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Ap rekriteFaz 4
- University of Wisconsin, Madison
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Ap rekriteEtid obsèvasyon
- University of Wisconsin-Madison, Madison
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Nashville, TN42 etid
- Seattle, WA42 etid
- Washington, DC38 etid
Lòt etid nan Madison
- Kansè kolorektal22 etid
- Kansè nan tete22 etid
- Kansè Metastatik21 etid
- Kansè Poumon ki pa ti selil16 etid
- Leksemi mieloïd egi16 etid
- Melanom15 etid
- Kansè (tout kalite)14 etid
- Kansè ovè13 etid
- Kansè lestomak11 etid
- Kansè poumon10 etid
- Kansè pankreyas10 etid
- Myelom Miltip9 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.